Neuroma Clinical Trial
— PPAPOfficial title:
Pathophysiology of Post Amputation Pain
The purpose of this study is to see how Post Amputation Pain (PAP) affects the body and brain by using sensory testing (such as pinprick testing), taking pictures of your brain (using a functional magnetic resonance imaging (fMRI) machine) and biomedical interventions (such as an injection of pain medicine). All medicines and the fMRI machine used during this study are FDA approved. The investigators hope that by learning the causes of PAP, the investigators can help future amputees.
Status | Completed |
Enrollment | 16 |
Est. completion date | December 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. At least 18 years old 2. Able to read and speak English and provide informed consent 3. Single Amputation, upper or lower. 4. Subject has chronic post amputation pain lasting longer than three months 5. Subject has healed amputation wounds 6. Pain must be =3 on a scale of 0-10, 0 being no pain, 10 being the worse pain imaginable. 7. If subjects pain is non-existent during fMRI scans, the subject needs to be willing to have their pain induced by targeting pain trigger points (for example, study's postdoctoral fellow would massage certain regions of the affected limb to trigger PAP). 8. Subject agrees to 1) Stop taking all aspirin seven days prior to their second visit (Bayer,Ecotrin,Alka Seltzer, etc.) 2) All inflammatory medications 48 hours prior to their second visit (Advil, Motrin, Indocin, Lodine , Ibuprofen, Aleve, Naproxen, etc. 3) Supplements such as Vitamin E and Fish Oil 48 hours prior to their second visit. 9. Subject agrees to continue other prescribed medications. 10. Subject is willing to have hypodermic needle injections and images taken of them (digital, thermal, and fMRI). 11. Able to understand and comply with all data collection methodology including electronic diary. 12. If female, is not pregnant and not currently attempting to conceive; if of childbearing potential, use of a highly effective method of birth control (as determined by Pl). Exclusion Criteria: 1. Subject is allergic to Isovue 300 or amide-type local anesthetics such as bupivicaine, lidocaine, or mepivacaine. 2. Subject has a diagnosis of bleeding diathesis or an immune compromise. 3. Subject has pain that is more severe than their post amputation pain. 4. Subject has a clinical diagnosis of fibromyalgia. 5. Subject has metal shavings and or is frequently in an environment where there is metal work being done or significant amounts of metal shavings. 6. Subject has ferrous metal implants, aneurism clips, bioelectric devices, and other implants which can be affected by the magnetic field of the MRI. 7. Subject is claustrophobic. 8. Subject weighs more than 300 pounds. 9. Subject plans to start new pain treatments or therapies during the study (e.g. new pain medication, injections, PT, surgery). |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Rehabilitation Institute of Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Rehabilitation Institute of Chicago | Northwestern University, United States Department of Defense |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Pain | Pain rating before and after injection on a 0-10 NRS pain scale (0=no pain, 10= worst pain imaginable) | Pain rating before and at 15 minutes and 1 hour post injection | No |
Secondary | Change in Perceived Disability (PDI) | The PDI is a seven-item validated instrument that assesses perceived disability in 7 key life areas. The Pain Disability Scale is a scale from 0-70 where 0= no disability and 70=the most disability | PDI collected pre injection and 1 week post injection | No |
Secondary | Change in Perceived Anxiety (PASS) | The Pain Anxitey Symptoms Scale (PASS) is a validated instrument that assesses anxiety in.The PASS is a scale from 0-100 where 0= no anxiety and 100=the most anxiety | PASS collected pre injection and 1 week post injection | No |
Secondary | Change in Depression (CES-D 10) | The Center for Epidemiologic Studies Short Depression Scale (CES-D 10) is a validated instrument that assesses depression. The CES-D 10 is a scale from 0-30 where 0= no depression and 30=the most depression | CES-D 10 collected pre injection and 1 week post injection | No |
Secondary | Pain Visual Analogue Scale (VAS) | The Pain Visual Analogue Scale (VAS) is a scale from 0-100 where 0= no pain and 100=the worst pain | VAS collected pre injection and 1 week post injection | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
Completed |
NCT00130962 -
ALGRX 4975 in the Treatment of Patients With Morton's Neuroma
|
Phase 2 | |
Recruiting |
NCT05008185 -
Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation
|
||
Completed |
NCT02205385 -
Targeted Reinnervation as a Means to Treat Neuromas Associated With Major Limb Amputation
|
N/A | |
Completed |
NCT02316262 -
Targeted Reinnervation for Neuromas as a Means to Improve Prosthesis Control in Major Limb Amputation
|
N/A | |
Completed |
NCT04931056 -
A Post Market Clinical Follow-up Study on Biomet Microfixation HTR PEKK (Midface), Facial & Mandibular Plates.
|
||
Completed |
NCT02528266 -
Surgical Treatment of Symptomatic Neuroma "Stop Neuroma"
|
N/A | |
Withdrawn |
NCT01374191 -
Botulinum Toxin Type A for Neuroma Pain
|
Phase 2 | |
Enrolling by invitation |
NCT06164392 -
Evaluation of Neuroma Perfusion With Indocyanine Green Fluorescence Angiography
|
Phase 4 | |
Completed |
NCT03484429 -
Postoperative Peripheral Nerve Stimulation for Management of Post-amputation Pain
|
N/A | |
Completed |
NCT03051113 -
Identification of Neuromas by High Resolution Ultrasound in Patients With Peripheral Nerve Injury and Amputations
|
||
Completed |
NCT02993276 -
Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma
|